Brought to you by 
Calistoga's Series C rakes in $40mm
25 Feb 2021
Executive Summary
Calistoga Pharmaceuticals Inc. (developing PI3K inhibitors for cancer and inflammatory diseases) raised $40mm through its Series C round. New buyer Quogue Capital led and was joined by additional new investor Latterell Venture Partners as well as existing backers Alta Partners, Amgen Ventures, Frazier Healthcare, and Three Arch Partners.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Calistoga's Series C rakes in $40mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice